newsfilter
← Latest News
GlobeNewswire·

Royalty Pharma Reports Q4 and Full Year 2025 Results

Portfolio Receipts of $874 million in Q4 2025 and $3,254 million for FY 2025 Portfolio Receipts growth of 18% in Q4 2025 and 16% for FY 2025Net cash provided by operating activities of $827 million in Q4 2025 and